Abstract:Background Despite the important breakthroughs of immune checkpoint blockade (ICB) therapy in multiple primary cancers, responses of ICB therapy in bone metastases remain extremely poor, largely due to the highly immunosuppressive bone metastasis microenvironment. Tumor-associated neutrophils have recently been reported to have critical impact in the responses of cancer immunotherapies. However, the role of neutrophils within bone metastasis microenvironment is still unknown. Here, we aim to explore the impact of immature neutrophils druing bone metastasis progression, and assess immunotherapies targeting neutrophils to improve ICB therapy in bone metastases. Methods RNA-seq and mass-spectrum data of bone metastasis samples from publicly available databases and our center were obtained. Mouse bone metastasis models from gastric, breast and lung cancer were established, and in vivo treatment efficacy of DKK1 and/or PD-1 blockade was evaluated by micro-computed tomography (CT), micro-magnetic resonance imaging (MRI) and immunohistochemistry (IHC) staining. Impacts of DKK1 on the bone-tumor microenvironment were explored via in vivo immune analysis. The impact of DKK1 on the maturation, function and phenotype of neutrophils was analyzed via in vitro co-culture models. Results The proportion of neutrophils within bone metastasis microenvironment of breast cancer model was gradually increased, and neutrophils gradually became immature (Ly6Ghigh, CD101-, CXCR2-, CXCR4+) during bone metastasis progression, with immature neutrophils occupied the most proportion (80%) at day 14. Meanwhile, analysis of bone metastasis samples from patients identified that DKK1 expression was significantly up-regulated in both mRNA and protein levels. DKK1 directly induced neutrophils to become immature in vitro, and immature neutrophils induced by DKK1 exhibited strong immunosuppressive capacity to inhibit the tumor-killing ability of CD8+ T cells in vitro co-culture models. Next, using multiple bone metastasis mouse models, we observed that DKK1 blockade with murine DKK1 antibody (mDKN-01) significantly controlled the tumor burden of bone metastases and alleviated bone destruction. Results of flow cytometry and immunofluorescence staining on bone metastasis samples demonstrated immature neutrophils were effectively reversed, and both innate and adaptive anti-tumor immunity were improved after DKK1 blockade. Finally, reversion of immature neutrophils by DKK1 blockade remarkedly enhanced the efficacy of PD-1 blockade in bone metastases, and complete response (CR) was observed with combined blockade of DKK1 and PD-1. Conclusions Our study provides novel insights into the critical impact of the immature neutrophils in the immunosuppressive bone metastasis microenvironment. DKK1 is a potential immunotherapeutic target for bone metastases, and dual blockade of DKK1 and PD-1 is a promising combination immunotherapy strategy for patients with bone metastasis. Ethics Approval Collection and analysis of tumor samples were approved by the Ethics Committee of Nanjing University Medical School Affiliated Drum Tower Hospital (2021–324-01). All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (2020AE01064). Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers

Abstract 5285: DKK1 blockade inhibits progression of bone metastases via multiple mechanisms and synergize with zoledronate treatment

940 Targeting DKK1 to Reverse Immunosuppressive Macrophages and Enhance PD-1 Blockade Therapy in Gastric Cancer

Dickkopf-related Protein 1, a New Biomarker for Local Immune Status and Poor Prognosis among Patients with Colorectal Liver Oligometastases: a Retrospective Study.

Dickkopf-1: A Promising Target for Cancer Immunotherapy

971 Immature Neutrophils Inhibit Anti-Tumor Immunity and Impede Checkpoint Blockade Therapy in Bone Metastases

Serum Dickkopf-1 As a Clinical and Prognostic Factor in Non-Small Cell Lung Cancer Patients with Bone Metastases

Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1

Effects of Dickkopf-1 (DKK-1) on Prostate Cancer Growth and Bone Metastasis

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01

Dickkopf 1 Impairs the Tumor Response to PD-1 Blockade by Inactivating CD8+ T Cells in Deficient Mismatch Repair Colorectal Cancer

Evolving functions of Dickkopf-1 in cancer and immunity

The Biological Effects of Dickkopf1 on Small Cell Lung Cancer Cells and Bone Metastasis

Abstract LB100: Dickkopf-1 induces breast cancer progression by limiting T cell infiltration into the tumor microenvironment

Effects of DKK1 Overexpression on Bone Metastasis of SBC-3 Cells.

Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention

Lung Cancer-Derived Dickkopf1 is Associated with Bone Metastasis and the Mechanism Involves the Inhibition of Osteoblast Differentiation.

Abstract 3925: Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity

Advances in the Role of Dickkopf (dkk1)in Myeloma Bone Disease and Its Targeted Therapy

DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer

Abstract 5793: Functional DKK1 antibodies binding to cysteine-rich domain 1 or 2 of hDKK1 demonstrate antagonistic activities on tumor suppression or TCF/LEF signaling